EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management

Federica Agnello iD, Salvatore Ingala, Giulia Laterra iD, Lorenzo Scalia iD, Marco Barbanti iD

Journal of Clinical Medicine · 22.02.2024 · 13 (5) · 1251

DOI: 10.3390/jcm13051251 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.02.2024. Verfasst von Federica Agnello und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels of low-density lipoprotein cholesterol (LDL-C) recognized as a central and modifiable risk factor. The effectiveness of lipid-lowering therapy (LLT) in mitigating ASCVD risk is well established, with studies revealing a substantial reduction in major ischemic events correlating with LDL-C reduction. While statins, often combined with ezetimibe, remain fundamental in dyslipidemia management, a significant proportion of patients on statin therapy continue to experience cardiovascular events. Recent pharmacological advancements, driven by a deeper understanding of atherogenesis, have unveiled novel therapeutic targets and potent drugs. Notably, agents like bempedoic acid and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab, alirocumab, inclisiran) have emerged as effective options to intensify LLT and achieve LDL-C goals, addressing limitations associated with statins, such as myopathy. Molecular insights into alternative pathways have spurred the investigation of emerging agents, offering promising perspectives for novel medications with efficacy comparable to established treatments, associated with advantages in cost and administration. This review provides a comprehensive overview of the evolving landscape of lipid-lowering strategies, highlighting the progress made in addressing ASCVD risk and the potential of upcoming therapies to further optimize cardiovascular prevention.

Schlagwörter

Stichwörter der Autor:innen

ACSLDL-CPCSK9ibempedoic aciddyslipidemiastatin

Autor:innen und Institutionen

  • Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy.
  • Faculty of Medicine and Surgery, Università degli Studi di Enna "Kore", 94100 Enna, Italy.

ORCID-Profile: Federica Agnello, Giulia Laterra, Lorenzo Scalia, Marco Barbanti

Zitieren

APA

Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024). Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. Journal of Clinical Medicine, 13(5), 1251. https://doi.org/10.3390/jcm13051251

Vancouver

Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. Journal of Clinical Medicine. 2024;13(5):1251. doi:10.3390/jcm13051251

BibTeX
@article{Agnello2024,
  author = {Agnello, Federica and Ingala, Salvatore and Laterra, Giulia and Scalia, Lorenzo and Barbanti, Marco},
  title = {Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {1251},
  doi = {10.3390/jcm13051251}
}
Kostenlos starten →